These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 33335233

  • 1. Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.
    Xu L, Chen LY.
    Sci Rep; 2020 Dec 17; 10(1):22267. PubMed ID: 33335233
    [Abstract] [Full Text] [Related]

  • 2. Danazol Inhibits Cytochrome P450 2J2 Activity in a Substrate-independent Manner.
    Lee E, Wu Z, Shon JC, Liu KH.
    Drug Metab Dispos; 2015 Aug 17; 43(8):1250-3. PubMed ID: 26048912
    [Abstract] [Full Text] [Related]

  • 3. Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
    Lee CA, Jones JP, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.
    Drug Metab Dispos; 2012 May 17; 40(5):943-51. PubMed ID: 22328583
    [Abstract] [Full Text] [Related]

  • 4. Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2.
    Lafite P, André F, Graves JP, Zeldin DC, Dansette PM, Mansuy D.
    Int J Mol Sci; 2018 Jul 16; 19(7):. PubMed ID: 30012976
    [Abstract] [Full Text] [Related]

  • 5. Atypical kinetics of cytochrome P450 2J2: Epoxidation of arachidonic acid and reversible inhibition by xenobiotic inhibitors.
    Leow JWH, Verma RK, Lim ABH, Fan H, Chan ECY.
    Eur J Pharm Sci; 2021 Sep 01; 164():105889. PubMed ID: 34044117
    [Abstract] [Full Text] [Related]

  • 6. Identification of novel substrates for human cytochrome P450 2J2.
    Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP, Freiwald S, Zientek M, Totah RA.
    Drug Metab Dispos; 2010 Feb 01; 38(2):347-56. PubMed ID: 19923256
    [Abstract] [Full Text] [Related]

  • 7. Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.
    Evangelista EA, Kaspera R, Mokadam NA, Jones JP, Totah RA.
    Drug Metab Dispos; 2013 Dec 01; 41(12):2087-94. PubMed ID: 24021950
    [Abstract] [Full Text] [Related]

  • 8. The inhibitory potential of Broussochalcone A for the human cytochrome P450 2J2 isoform and its anti-cancer effects via FOXO3 activation.
    Park SH, Lee J, Shon JC, Phuc NM, Jee JG, Liu KH.
    Phytomedicine; 2018 Mar 15; 42():199-206. PubMed ID: 29655687
    [Abstract] [Full Text] [Related]

  • 9. Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites.
    Karkhanis A, Lam HY, Venkatesan G, Koh SK, Chai CL, Zhou L, Hong Y, Kojodjojo P, Chan EC.
    Biochem Pharmacol; 2016 May 01; 107():67-80. PubMed ID: 26972388
    [Abstract] [Full Text] [Related]

  • 10. Plant natural product plumbagin presents potent inhibitory effect on human cytochrome P450 2J2 enzyme.
    Lu J, Liu D, Zhou X, Chen A, Jiang Z, Ye X, Liu M, Wang X.
    Phytomedicine; 2018 Jan 15; 39():137-145. PubMed ID: 29433675
    [Abstract] [Full Text] [Related]

  • 11. Probing ligand binding modes of human cytochrome P450 2J2 by homology modeling, molecular dynamics simulation, and flexible molecular docking.
    Li W, Tang Y, Liu H, Cheng J, Zhu W, Jiang H.
    Proteins; 2008 May 01; 71(2):938-49. PubMed ID: 18004755
    [Abstract] [Full Text] [Related]

  • 12. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.
    Matsumoto S, Hirama T, Matsubara T, Nagata K, Yamazoe Y.
    Drug Metab Dispos; 2002 Nov 01; 30(11):1240-5. PubMed ID: 12386130
    [Abstract] [Full Text] [Related]

  • 13. Terfenadone is a strong inhibitor of CYP2J2 present in the human liver and intestinal microsomes.
    Lee E, Kim JH, Shon JC, Wu Z, Kim HJ, Gim M, Lee T, Liu KH.
    Drug Metab Pharmacokinet; 2018 Jun 01; 33(3):159-163. PubMed ID: 29759885
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of Cytochrome P450 2J2-Mediated Metabolism of Rivaroxaban and Arachidonic Acid by Ibrutinib and Osimertinib.
    Wang Z, Yong Chan EC.
    Drug Metab Dispos; 2022 Oct 01; 50(10):1332-1341. PubMed ID: 35817438
    [Abstract] [Full Text] [Related]

  • 15. Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity.
    Lee SS, Jeong HE, Liu KH, Ryu JY, Moon T, Yoon CN, Oh SJ, Yun CH, Shin JG.
    Pharmacogenet Genomics; 2005 Feb 01; 15(2):105-13. PubMed ID: 15861034
    [Abstract] [Full Text] [Related]

  • 16. [Research progress of human cytochrome P450 2J2 and its ligands].
    Ma HY, Ning J, Ge GB, Yang L, Hao DC.
    Yao Xue Xue Bao; 2017 Jan 01; 52(1):26-33. PubMed ID: 29911373
    [Abstract] [Full Text] [Related]

  • 17. Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies.
    Ducassou L, Jonasson G, Dhers L, Pietrancosta N, Ramassamy B, Xu-Li Y, Loriot MA, Beaune P, Bertho G, Lombard M, Mansuy D, André F, Boucher JL.
    Biochim Biophys Acta; 2015 Jul 01; 1850(7):1426-37. PubMed ID: 25857771
    [Abstract] [Full Text] [Related]

  • 18. Unusual regioselectivity and active site topology of human cytochrome P450 2J2.
    Lafite P, André F, Zeldin DC, Dansette PM, Mansuy D.
    Biochemistry; 2007 Sep 11; 46(36):10237-47. PubMed ID: 17705402
    [Abstract] [Full Text] [Related]

  • 19. Computational modelling of the binding of arachidonic acid to the human monooxygenase CYP2J2.
    Proietti G, Abelak KK, Bishop-Bailey D, Macchiarulo A, Nobeli I.
    J Mol Model; 2016 Nov 11; 22(11):279. PubMed ID: 27796781
    [Abstract] [Full Text] [Related]

  • 20. The development of novel cytochrome P450 2J2 (CYP2J2) inhibitor and the underlying interaction between inhibitor and CYP2J2.
    Tian X, Zhou M, Ning J, Deng X, Feng L, Huang H, Yao D, Ma X.
    J Enzyme Inhib Med Chem; 2021 Dec 11; 36(1):737-748. PubMed ID: 33682565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.